drugset / Trial / NCT00758160

The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00758160 ↗

Phase 4 Completed 296 enrolled Johnson & Johnson Taiwan Ltd
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether familial relationships and psychological status of participants or caregivers as well as Attention Deficit Hyperactivity Disorder (ADHD) symptoms of participants can be improved by switching from Immediate-release Methylphenidate (IR-MPH) to Osmotic Release Oral Delivery System Methylphenidate (OROS-MPH).

Timeline

Start
2008-03
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 18 mg Oral
Subject Methylphenidate Small molecule 36 mg Oral
Subject Methylphenidate Small molecule 54 mg Oral